Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.

Mayo Clinic proceedings - 1 Sept 2016

Thanarajasingam Gita, Edell Eric S, Markovic Svetomir M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Airway Obstruction
Share to Anaplastic Lymphoma Kinase
Share to Bronchoscopy
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma, T-Cell

Share to Positron-Emission Tomography

Share to Pyrazoles

Share to Pyridines

Source

Identifiers

PMID: 27594191
DOI: 10.1016/j.mayocp.2016.06.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.PMID 27594191Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisSemantic proximity Read ↗

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.Semantic proximity Read ↗

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Semantic proximity Read ↗

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Semantic proximity Read ↗

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.Semantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell TherapySemantic proximity Read ↗

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.Semantic proximity Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.